Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01944423 · ClinicalTrials.gov registry record · Early Phase 1
Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine
A Early Phase 1 study, sponsored by University of Texas at Austin.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 53
- Enrollment target
NCT01944423: Completed Early Phase 1 study, sponsored by University of Texas at Austin.
NCT01944423 is a Early Phase 1 study that has completed, run by University of Texas at Austin. The registered enrollment target is 53 participants, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01944423, a Early Phase 1 study, has completed, sponsored by University of Texas at Austin.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of the current study is to evaluate the efficacy of d-cycloserine in augmenting treatment of smoking cessation for individuals with panic attacks. The investigators hypothesize that individuals receiving DCS (versus those receiving placebo) will evidence greater smoking abstinence rates and decreased panic symptoms after receiving a combined CBT-based treatment for smokers with panic attacks.
Primary Outcome
Smoking status will be assessed at baseline and each of the follow-up assessments using point prevalence abstinence (PPA) measures verified with carbon monoxide and saliva cotinine.
Interventions
- DRUG d-cycloserine
- DRUG Pill Placebo
- DRUG Nicotine replacement therapy
- BEHAVIORAL Panic and Smoking Reduction Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2013-10 |
| Est. Completion | 2018-10 |
| Phase | Early Phase 1 |
What the finished NCT01944423 record still lists
NCT01944423 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which d-cycloserine is the first listed.
NCT01944423 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01944423 about?
NCT01944423 is a clinical study titled "Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine". The purpose of the current study is to evaluate the efficacy of d-cycloserine in augmenting treatment of smoking cessation for individuals with panic attacks. The investigators hypothesize that individuals receiving DCS (versus those receiving placebo) will evidence greater smoking abstinence rates ...
What is the current status of trial NCT01944423?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 53 participants. The study started on 2013-10. Estimated completion is 2018-10.
What interventions are being tested in trial NCT01944423?
The interventions under investigation include: d-cycloserine (DRUG), Pill Placebo (DRUG), Nicotine replacement therapy (DRUG), Panic and Smoking Reduction Treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT01944423?
This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01944423's enrollment target sits among peer trials
53 472nd of 2000 higher than 1,524 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia